Cannabidiol for Epilepsy: What the Evidence Shows
Cannabidiol (CBD) is not a general treatment for epilepsy, but a purified, prescription formulation has demonstrated benefits for seizures linked to several severe epilepsy syndromes. In the United States, the Food and Drug Administration (FDA) has approved Epidiolex for seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex in patients 1 year of age and older. The evidence does not establish that over-the-counter CBD oils, edibles, or other cannabis products are effective substitutes.
CBD is a cannabis-derived compound that generally does not produce the intoxicating “high” associated with delta-9-tetrahydrocannabinol (THC). Its lack of intoxicating effects, however, does not mean that it is risk-free or appropriate for every person with epilepsy. Epilepsy includes many seizure types and syndromes, and treatment decisions depend on the specific diagnosis, other medications, age, and overall health. The Epilepsy Foundation’s overview of epilepsy syndromes provides additional background on how these conditions differ.
What early research found
A 2014 review by Devinsky and colleagues summarized laboratory, animal, and early clinical evidence suggesting that CBD could have anticonvulsant effects. The authors described CBD as a promising candidate but emphasized that controlled clinical trials were needed to determine its effectiveness, dosing, and safety. The full review is available through PubMed.
In a 2016 open-label interventional trial, researchers gave pharmaceutical CBD in addition to existing antiseizure medications to 214 children and young adults with highly treatment-resistant epilepsy. Of the 137 participants included in the efficacy analysis, the median reduction in monthly motor seizures during the 12-week treatment period was 36.5%.
That result was encouraging but could not by itself establish that CBD caused the improvement. The study had no placebo control, and participants and investigators knew that CBD was being given. The trial also included people with different forms and causes of epilepsy. Such factors can influence reported seizure frequency and make open-label findings less reliable than randomized, blinded trials.
Evidence from randomized clinical trials
Subsequent placebo-controlled trials provided stronger evidence for specific epilepsy syndromes. In a 2017 randomized trial of 120 children and young adults with drug-resistant Dravet syndrome, the median frequency of convulsive seizures fell by 38.9% with pharmaceutical CBD, compared with 13.3% with placebo. The study was published in the New England Journal of Medicine.
A 2018 randomized trial involving 225 patients with Lennox–Gastaut syndrome tested CBD as an add-on treatment. Median drop-seizure frequency fell by 41.9% with a 20-milligram-per-kilogram daily dose and 37.2% with a 10-milligram-per-kilogram dose, compared with 17.2% with placebo. The findings, reported in the New England Journal of Medicine, support CBD as an adjunctive treatment for this syndrome—not as a cure or replacement for standard antiseizure therapy.
A 2020 systematic review of cannabis-based products in pediatric epilepsy reached a similar, qualified conclusion. The review found that randomized and nonrandomized studies generally suggested reductions in seizure frequency and more treatment responders, but also found increased gastrointestinal adverse effects. The authors noted that the evidence was limited by differences among products, small studies, and methodological weaknesses. The review is indexed in PubMed.
What FDA approval means
FDA approval applies to Epidiolex, a standardized oral solution containing highly purified CBD, used under medical supervision. It does not apply to the many CBD products sold online or in retail stores. Those products may differ in CBD concentration, contain detectable THC or contaminants, and have not undergone FDA review to establish a safe and effective dose for epilepsy. The FDA explains the distinction in its guidance on CBD-containing products.
Epidiolex can cause sleepiness, decreased appetite, diarrhea, fatigue, and elevations in liver enzymes. Liver injury is an important safety concern, particularly when CBD is taken with other medications that affect the liver. CBD can also interact with antiseizure drugs, including clobazam. The current Epidiolex prescribing information describes required monitoring, dosing, drug interactions, and warnings.
The World Health Organization’s 2018 critical review concluded that CBD itself is not intoxicating and is not associated with the same abuse and dependence profile as THC. The review also acknowledged that therapeutic claims required better clinical evidence. A favorable general safety assessment should not be interpreted as proof that every CBD product is safe or that CBD is effective for every type of epilepsy. The report is available from the World Health Organization.
Limitations and practical considerations
The strongest evidence concerns pharmaceutical CBD used alongside other medications for Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex. Evidence is less conclusive for other epilepsy types, and CBD may not help all patients. Seizure changes should be assessed with a clinician rather than by stopping prescribed treatment or switching to an unregulated cannabis product.
Anyone considering CBD for epilepsy should discuss it with a neurologist or other qualified healthcare professional. A clinician can determine whether the person’s epilepsy matches an evidence-supported indication, review potential drug interactions, select an appropriate formulation, and arrange liver-function monitoring when necessary. CBD may be a useful treatment for some severe, treatment-resistant epilepsies, but its benefits and risks depend heavily on the product, dose, seizure syndrome, and medical supervision.
